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OBJECTIVE—Recent genome-wide association studies (GWASs)
related common variants in the interleukin-6 (Il-6) receptor
(IL6R) gene to plasma C-reactive protein (CRP) concentrations.
Because IL6R variants were previously associated with IL-6
levels, we tested whether the associations with CRP were
independent of IL-6 and the interactions between IL6R variants
and CRP in relation to diabetes risk.
RESEARCH DESIGN AND METHODS—Plasma CRP and IL-6
levels and 10 IL6R polymorphisms were determined in a nested
case-control study of 633 diabetic and 692 healthy Caucasian
women.
RESULTS—In both nondiabetic and diabetic women, IL6R
polymorphisms were associated with plasma CRP levels, inde-
pendent of IL-6 concentration. After adjustment of IL-6 levels,
CRP concentrations in the genotype AA, AC, and CC of the
GWAS polymorphism rs8192284 were 0.32, 0.26, and 0.24 pg/ml,
respectively, among nondiabetic women (P for trend  0.003;
false discovery rate [FDR]  0.01) and 0.63, 0.48, and 0.43 pg/ml
among diabetic women (P for trend 0.0001; FDR  0.0001).
Haplotypes inferred from polymorphisms within a linkage dis-
equilibrium block including rs8192284 were also signiﬁcantly
associated with CRP levels (P  0.0002). In an exploratory
analysis, rs8192284 showed signiﬁcant interactions with CRP
levels in relation to diabetes risk (P for interaction  0.026). The
odds ratios across increasing quartiles of CRP were 2.19 (95% CI
1.42–3.36), 2.03 (1.27–3.23), and 2.92 (1.77–4.82) in the carriers of
allele-C and 2.21 (1.18–4.12), 3.77 (1.87–7.57), and 5.02 (2.4–10.5)
in the noncarriers.
CONCLUSIONS—IL6R variants were signiﬁcantly associated
with plasma CRP, independent of IL-6 levels. IL6R variants may
interact with CRP in predicting diabetes risk. Diabetes 58:
275–278, 2009
C
hronic systemic inﬂammation can induce insu-
lin resistance and is a key mechanism linking
obesity and diabetes (1). As a nonspeciﬁc
marker of systemic inﬂammation, C-reactive
protein (CRP) is an acute-phase reactant synthesized in
the liver in response to cytokines (2), especially interleu-
kin-6 (IL-6) (3). In epidemiological studies, circulating CRP
levels signiﬁcantly predict the risk of type 2 diabetes
(4–6).
In an earlier analysis (7), we found that the common
variants in the IL-6 receptor (IL6R) gene, especially a
single nucleotide polymorphism (SNP) rs8192284, were
signiﬁcantly related to high-plasma IL-6 concentration.
Similar associations between IL6R SNPs and IL-6 concen-
tration were also observed in an admixture study (8). In a
recent genome-wide association study (GWAS) on plasma
CRP levels among 6,345 apparently healthy women, com-
mon SNPs in the IL6R gene including rs8192284 were
associated with CRP concentration at genome-wide signif-
icance level (P  5  10
8) (9). Because of the close
relationship between IL-6 and CRP, we hypothesized that
the IL6R gene–CRP associations observed in the GWAS
might be secondary to the changes in circulating IL-6
levels.
To test this hypothesis, we examined the associations
between IL6R gene variants and CRP concentrations in
healthy and diabetic women, controlling for IL-6 levels. We
also assessed the interactions between IL6R SNPs and
plasma CRP levels in predicting the risk of type 2 diabetes.
RESEARCH DESIGN AND METHODS
The Nurses’ Health Study began in 1976 with the recruitment of 121,700 female
registered nurses (aged 30–55 years). Between 1989 and 1990, 32,826 women
provided blood. The medical history and lifestyle information were updated
every 2 years using a questionnaire (10). Samples for the present study were
selected from women who provided a blood sample and were free from
diabetes, cardiovascular disease, stroke, or cancer at the time of blood
collection. Incident cases of type 2 diabetes were deﬁned as self-reported
diabetes conﬁrmed by a validated supplementary questionnaire and diagnosed
at least 1 year after blood collection. We used National Diabetes Data Group
criteria (11) to deﬁne diabetes, because our subjects were diagnosed before
the release of the American Diabetes Association criteria in 1997. The validity
of this method has been conﬁrmed (12). We used the American Diabetes
Association diagnostic criteria for diagnosis of diabetes cases after the 1998
cycle (13). The incident cases were matched to control subjects who did not
report physician-diagnosed diabetes on age, month and year of blood draw,
and fasting status (14,15). In total, 1,325 European Caucasian women (633
diabetic patients and 692 control subjects) with plasma IL-6 and CRP
measures were included.
Assessment of plasma levels of CRP and IL-6 and of covariates. Blood
sample collection (between 1989 and 1990) and processing were previously
described (14,16). The assays were performed in 2003 using the stored blood
samples (in the vapor phase of liquid nitrogen freezers; the highest tempera-
ture is 130°C). Frozen plasma aliquots from case and control subjects were
selected for simultaneous analysis. Study samples were analyzed in randomly
ordered case-control pairs to further reduce systematic bias and interassay
variation. CRP levels were measured via a high-sensitivity latex-enhanced
immunonephelometric assay on a BN II analyzer (Dade Behring, Newark, DE).
Plasma concentrations of IL-6 were measured using a quantitative sandwich
enzyme immunoassay technique (Quantikine HS Immunoassay kit). The
coefﬁcient of variation was 3.8% for CRP and 5.9% for IL-6 (7,16). BMI was
calculated as weight in kilograms divided by the square of height in meters.
Physical activity was expressed as metabolic equivalent task (MET) hours
based on self-reported types and durations of activities over the previous year.
SNPs selection and genotype determination. DNA was extracted from the
buffy coat fraction of centrifuged blood using the QIAmp Blood kit (Qiagen,
Chatsworth, CA). Ten linkage disequilibrium tagging SNPs (rs4845618,
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DIABETES, VOL. 58, JANUARY 2009 275rs12083537, rs4075015, rs6684439, rs4845622, rs8192284, rs4329505, rs4240872,
rs2229238, and rs4845617) for IL6R were selected as previously described (7).
The tagging SNPs cover 94% allele variance. The polymorphisms were
genotyped using Taqman SNP allelic discrimination by means of an ABI
7900HT (Applied Biosystems, Foster City, CA). Replicate quality-control
samples (10%) were included and genotyped with 99% concordance. All
genotypes ﬁt Hardy-Weinberg equilibrium (HWE).
Statistical analyses. A 
2 test was used to assess whether the genotypes
were in HWE. General linear models were used to compare geometric mean
values of quantitative traits across groups. Plasma CRP and IL-6 were
logarithmically transformed to improve the normality. We adjusted for covari-
ates, including age (continuous), BMI (23, 23–24.9, 25–29.9, 30–34.9, or 35
kg/m
2), physical activity (1.5, 1.5–5.9, 6.0–11.9, 12–20.9, or 21.0 MET
h/week), smoking (never, past, or current), alcohol intake (nondrinker or
drinker [0.1–4.9, 5–10, or 10 g/day]), family history of diabetes, menopausal
status (pre- or postmenopausal [never, past, or current hormone use]), and
IL-6 levels (in quartiles). Because of the missing data in biomarkers and
genotyping, some matching pairs in the case-control design were broken.
Therefore, we used unconditional logistic regression as the primary analysis
in estimating odds ratios (ORs) for diabetes risk to avoid the loss of unpaired
samples. Conditional logistic regression yielded similar results (data not
shown). The interactions between polymorphisms and biomarkers were
examined using likelihood ratio test, with a comparison of the log likelihood
of the two models with and without the interaction terms.
To account for multiple statistical testing, we calculated false discovery
rate (FDR) for the analyses on the polymorphisms by the method of Benjamini
and Hochberg (17) using SAS procedure PROC MULTTEST. FDR estimates
the proportion of results declared positive that are actually false (18). The SAS
statistical package was used for the analyses (SAS, version 8.2 for UNIX).
Haplotype analysis was conducted based on the Stochastic-EM algorithm
using THESIAS program (19). All P values are two sided.
RESULTS
Table 1 shows age and age-adjusted baseline characteris-
tics according to rs8192284 genotypes for women with
both CRP and IL-6 measurements available. IL-6 levels
were higher in women with AC and CC genotypes com-
pared with those with AA genotype. The genotypes were
not associated with any other characteristics.
In nondiabetic women, the three SNPs rs6684439,
rs4845622, and rs8192284, which were in strong linkage
disequilibrium, were signiﬁcantly associated with low
plasma CRP levels after adjusting for IL-6 and other
covariates (Table 2). SNPs rs12083537 and rs4329505 were
associated with high plasma CRP levels. We calculated
FDR by the method of Benjamini and Hochberg (17) to
adjust for the multiple testing. The FDRs for all of these
associations were 0.05. In most cases, similar associa-
tions between IL6R polymorphisms and CRP levels were
observed in the diabetic patients.
We inferred the haplotypes from the polymorphisms
within the linkage disequilibrium block (including SNPs
rs6684439, rs4845622, rs8192284, rs4329505, rs4240872,
rs2229238, and rs4845617). Because rs6684439, rs4845622,
and rs8192284 are in nearly perfect linkage disequilibrium
(r
2  0.9), only rs8192284 was kept in haplotype inference,
together with the other four SNPs in this linkage disequi-
librium block (rs4845618, rs4329505, rs4240872, and
rs2229238). Five common haplotypes accounted for 96%
allele variance of the linkage disequilibrium block. Haplo-
types 21122 (P  0.039; 1, the common allele; 2, the minor
allele) and 11211 (P  0.0006) were associated with 0.13
(0.01–0.26) and 0.23 (0.10–0.37) pg/ml higher CRP levels,
respectively, compared with the most common haplotype
12111, adjusting for IL-6 and other covariates (Fig. 1). The
TABLE 1
Clinical characteristics of nondiabetic women according to the genotypes of SNP rs8192284
rs8192284
P value AA AC CC
Participants (n) 234 342 101
Age (years) 55  95 7  75 6  7 0.56
BMI (kg/m
2) 26.2  6.6 26.3  5.6 27.6  6.6 0.15
Physical activity (MET h/week) 12.9  15.4 16.3  19.4 14.8  13.2 0.07
Alcohol consumption (g/day) 6.34  11.0 5.54  9.62 5.31  7.87 0.54
Family history of diabetes 20.9 21 22.8 0.92
Current smoker 14.7 10.8 8 0.37
Postmenopausal status 76.1 81.3 78.2 0.31
IL-6 (ng/ml) 1.84  1.97 1.99  2.07 2.14  1.82 0.003
Data are percent or means  SD.
TABLE 2
Plasma CRP levels by IL6R genotypes in nondiabetic and diabetic women
Alleles
(major/minor)
Nondiabetic (pg/ml)
P* FDR
Diabetic (pg/ml)
P* FDR 11 12 22 11 12 22
rs4845617 G/A 0.27 (0.02) 0.26 (0.02) 0.30 (0.03) 0.34 0.38 0.52 (0.03) 0.51 (0.03) 0.57 (0.05) 0.94 0.94
rs12083537 T/C 0.27 (0.01) 0.28 (0.02) 0.29 (0.05) 0.009 0.02 0.54 (0.03) 0.49 (0.04) 0.51 (0.10) 0.07 0.11
rs4075015 T/A 0.28 (0.02) 0.27 (0.02) 0.31 (0.03) 0.2 0.27 0.49 (0.03) 0.53 (0.03) 0.51 (0.05) 0.34 0.38
rs6684439 C/T 0.30 (0.02) 0.27 (0.02) 0.24 (0.03) 0.006 0.015 0.60 (0.03) 0.49 (0.03) 0.41 (0.05) 0.0001 0.0001
rs4845618 A/C 0.27 (0.02) 0.28 (0.02) 0.28 (0.03) 0.55 0.58 0.49 (0.04) 0.52 (0.03) 0.59 (0.05) 0.01 0.018
rs4845622 T/G 0.31 (0.02) 0.27 (0.02) 0.24 (0.03) 0.0002 0.0008 0.61 (0.03) 0.49 (0.03) 0.41 (0.05) 0.0001 0.0001
rs8192284 A/C 0.32 (0.02) 0.26 (0.02) 0.24 (0.03) 0.003 0.01 0.63 (0.03) 0.48 (0.03) 0.43 (0.05) 0.0001 0.0001
rs4329505 T/C 0.27 (0.01) 0.32 (0.02) 0.27 (0.07) 0.004 0.011 0.49 (0.02) 0.57 (0.04) 0.81 (0.16) 0.0001 0.0001
rs4240872 A/G 0.27 (0.01) 0.29 (0.02) 0.27 (0.06) 0.31 0.38 0.51 (0.03) 0.53 (0.03) 0.61 (0.09) 0.07 0.11
rs2229238 G/A 0.27(0.01) 0.30 (0.02) 0.32 (0.08) 0.13 0.19 0.50 (0.02) 0.56 (0.04) 0.54 (0.11) 0.01 0.018
Data are means (SE) unless otherwise indicated. For each polymorphism, 11 represents the major allele homozygotes, 12 represents the
heterozygotes, and 22 represents the minor allele homozygotes; missing genotyping is not included. *Comparisons between carriers and
noncarriers adjusted for age, BMI, alcohol consumption, smoking, physical activity, family history of diabetes, menopausal status, and IL-6.
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signiﬁcant (P  0.0002).
Because SNP rs8192284 was a missense variant, related
to CRP in the GWAS, and showed the strongest associa-
tion with IL-6 levels in our previous study (7), we further
tested the interactions between this SNP and CRP levels in
relation to diabetes risk and observed signiﬁcant multipli-
cative interaction (P for interaction  0.026; Fig. 2). We
then examined the stratiﬁed associations between CRP
levels and diabetes risk by rs8192284 genotypes. To im-
prove power, we grouped the subjects into carriers and
noncarriers of the minor allele C. After adjusting for IL-6
levels and other covariates, the ORs across increasing
quartiles of CRP were 2.21 (95% CI 1.18–4.12), 3.77 (1.87–
7.57), and 5.02 (2.4–10.5) in the noncarriers; whereas in
the carriers, the ORs were 2.19 (1.42–3.36), 2.03 (1.27–
3.23), and 2.92 (1.77–4.82), respectively.
DISCUSSION
We found signiﬁcant associations between IL6R variants
and plasma CRP levels. Our results are consistent with the
ﬁndings from recent GWASs (9,20). We demonstrated that
the associations between IL6R variants and CRP levels are
independent of IL-6 concentration. In an exploratory anal-
ysis, we found IL6R variant rs8192284 signiﬁcantly inter-
acts with CRP levels in relation to diabetes risk. The
associations between CRP levels and increased diabetes
risk are more evident in women carrying the wild-type
genotype than in those with the minor allele C.
IL-6 is a pleiotropic cytokine that performs as the chief
stimulator of the production of CRP from the liver (21). In
epidemiological studies, circulating levels of IL-6 and CRP
are signiﬁcantly correlated (22). In our earlier analyses, we
found that IL6R variants are signiﬁcantly related to IL-6
levels (7). The same association was also observed in the
Health ABC study (8). Our data from the present study
suggest that the association between IL6R variants and
CRP levels is unlikely due to the changes in IL-6 levels,
because the IL6R gene–CRP association was independent
of IL-6 levels.
Because CRP and IL-6 are not the direct products of the
IL6R gene, the associations between IL6R variants and
these biomarkers are likely mediated by other metabolic
changes. SNP rs8192284 in the IL6R gene has been asso-
ciated with soluble IL6R levels (8). These data suggest that
IL6R variant may primarily affect IL6R levels and that the
changes in CRP and IL-6 are likely secondary.
The precise mechanisms underlying the opposite asso-
ciations of IL6R variant (rs8192284) with IL-6 and CRP are
not clear. The differing associations are particularly puz-
zling considering that IL-6 may stimulate the product of
CRP in the liver. However, the data from our study are
highly consistent with the GWAS and previous studies
(8,9,20). We suspect that the genotype-related changes in
CRP and IL-6 levels may be parallel changes, rather than
sequential events, both induced by the alterations in IL6R
products.
Subclinical systemic inﬂammation is now considered an
important mechanism leading to insulin resistance and
type 2 diabetes (23). Epidemiological studies have docu-
mented that circulating inﬂammatory markers, including
CRP, signiﬁcantly predict diabetes risk (4–6). Previous
studies indicate that polymorphisms affecting CRP levels
may also inﬂuence the risk of type 2 diabetes (24).
Although IL6R SNPs were not signiﬁcantly associated
with the incidence of diabetes in our study sample (7), the
exploratory analysis indicated that the genetic variant
might modify the association between CRP levels and
diabetes risk. The associations between CRP and in-
creased risk of type 2 diabetes are more evident in women
carrying genotype AA of rs8192284 compared with those
carrying the minor allele C. This observation reﬂects a
synergic effect of IL6R genotype and CRP levels on the
development of diabetes. The observed interaction needs
to be conﬁrmed in future studies.
Several limitations need to be considered. SNP
rs4129267 reported by the GWAS (9) was not typed in the
present study. However, this SNP is in near perfect linkage
disequilibrium with rs8192284 (D	1 and r
2  0.96;
HapMap, CEU). Population stratiﬁcation arising from eth-
nic admixture may cause spurious associations. However,
the present study was less likely to be inﬂuenced by
population stratiﬁcation because the study populations
were highly homogeneous, including only European Cau-
casians. In addition, our analyses were restricted to
women and therefore may not be generalized to men.
In summary, we demonstrated that the IL6R variants
are signiﬁcantly associated with plasma CRP levels, inde-
pendent of IL-6 levels. In addition, IL6R variant interacts
with CRP in relation to diabetes risk. Further research is
warranted to elucidate the potential mechanisms underly-
ing the associations between IL6R variants and the oppo-
site changes in CRP and IL-6 levels.
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rs4329505, rs4240872, and rs2229238) associations with plasma CRP
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and IL-6.
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